| abstract |
The pharmaceutical composition may comprise from about 2 mg to about 4 mg of 6β, 7β; 15β, 16β-dimethylene-3-oxo-17α-pregin-4-ene-21, corresponding to the daily dose, based on the dosage composition, 17-carbolactone (drospyrenone) as the first active agent, and from about 0.01 mg to about 0.05 mg of 17α-ethynylestradiol (ethynylestradiol) corresponding to the daily dose as the second active agent, With one or more pharmaceutically acceptable carriers or excipients. In one embodiment, the composition consists of several daily dosage units contained in one packaging unit that can be individually packaged and removed one by one, and continuing oral administration for a period of 21 days or more. For the purpose, the daily dosage unit comprises a combination of drospirenone and ethynylestradiol. The composition further comprises up to seven daily dosage units containing no active agent or containing only ethynylestradiol. |